An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., Friedlander, M., Gourley, C., Plummer, R., Rustin, G., Sessa, C., Leunen, K., Ledermann, J., Swaisland, H., Fielding, A., Bannister, W., Nicum, S., Molife, L. R.
Published in Targeted oncology (01.06.2016)
Published in Targeted oncology (01.06.2016)
Get full text
Journal Article
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
Dean, E, Middleton, M R, Pwint, T, Swaisland, H, Carmichael, J, Goodege-Kunwar, P, Ranson, M
Published in British journal of cancer (31.01.2012)
Published in British journal of cancer (31.01.2012)
Get full text
Journal Article
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
Baselga, J, Rischin, D, Ranson, M, Calvert, H, Raymond, E, Kieback, D G, Kaye, S B, Gianni, L, Harris, A, Bjork, T, Averbuch, S D, Feyereislova, A, Swaisland, H, Rojo, F, Albanell, J
Published in Journal of clinical oncology (01.11.2002)
Published in Journal of clinical oncology (01.11.2002)
Get full text
Journal Article
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors
Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., Dong, R.-P., Fukuoka, M.
Published in Annals of oncology (01.06.2003)
Published in Annals of oncology (01.06.2003)
Get full text
Journal Article
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man
McKillop, D., Hutchison, M., Partridge, E. A., Bushby, N., Cooper, C. M. F., Clarkson-Jones, J. A., Herron, W., Swaisland, H. C.
Published in Xenobiotica (01.10.2004)
Published in Xenobiotica (01.10.2004)
Get full text
Journal Article
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
Boss, D.S., Schwartz, G.K., Middleton, M.R., Amakye, D.D., Swaisland, H., Midgley, R.S., Ranson, M., Danson, S., Calvert, H., Plummer, R., Morris, C., Carvajal, R.D., Chirieac, L.R., Schellens, J.H.M., Shapiro, G.I.
Published in Annals of oncology (01.04.2010)
Published in Annals of oncology (01.04.2010)
Get full text
Journal Article
A sensitive assay for ZD1839 (Iressa ) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials
Jones, H.K, Stafford, L.E, Swaisland, H.C, Payne, R
Published in Journal of pharmaceutical and biomedical analysis (20.06.2002)
Published in Journal of pharmaceutical and biomedical analysis (20.06.2002)
Get full text
Journal Article
Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer
Ranson, M, Wilson, R H, O'Sullivan, J M, Maruoka, M, Yamaguchi, A, Cowan, R A, Logue, J P, Tomkinson, H, Tominaga, N, Swaisland, H, Oliver, S, Usami, M
Published in International journal of clinical pharmacology and therapeutics (01.11.2010)
Published in International journal of clinical pharmacology and therapeutics (01.11.2010)
Get more information
Journal Article
In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers
Swaisland, H. C., Oliver, S. D., Morris, T., Jones, H. K., Bakhtyari, A., Mackey, A., McCormick, A. D., Slamon, D., Hargreaves, J. A., Millar, A., Taboada, M. T.
Published in Xenobiotica (01.06.2009)
Published in Xenobiotica (01.06.2009)
Get full text
Journal Article
405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments
Ang, J.E, Clarkson-Jones, J.A, Swaisland, H, Brunetto, A.T, Lal, R, Farnsworth, A.P, Molife, L.R, Kaye, S.B, Carmichael, J, de Bono, J.S
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
1238 An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function
Tomkinson, H.K, Weil, A, Engelhardt, E, Schmid, K, Oliver, S, Morris, T, Swaisland, H, Taboada, M
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
724 POSTER Metabolism of [14 C]-ZD4054 in healthy volunteers
Clarkson-Jones, J, Kenyon, A, Kemp, J, Lenz, E, Oliver, S, Phillips, P, Sandall, D, Swaisland, H
Published in European journal of cancer supplements (2007)
Published in European journal of cancer supplements (2007)
Get full text
Journal Article
718 POSTER The pharmacokinetic and tolerability profile of once-daily oral ZD4054 in Japanese and Caucasian patients with hormone-refractory prostate cancer
Ranson, M, Usami, M, Maruoka, M, Yamaguchi, A, Cowan, R.A, Logue, J.P, Jones, H, Tominaga, N, Swaisland, H, Oliver, S
Published in European journal of cancer supplements (2007)
Published in European journal of cancer supplements (2007)
Get full text
Journal Article
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
RANSON, Malcolm, HAMMOND, Lisa A, FEYEREISLOVA, Andrea, SWAISLAND, Helen, ROWINSKY, Eric K, FERRY, David, KRIS, Mark, TULLO, Andrew, MURRAY, Philip I, MILLER, Vince, AVERBUCH, Steve, OCHS, Judy, MORRIS, Charles
Published in Journal of clinical oncology (01.05.2002)
Published in Journal of clinical oncology (01.05.2002)
Get full text
Journal Article
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
HERBST, Roy S, MADDOX, Anne-Marie, OCHS, Judith, MUCCI LORUSSO, Patricia, ROTHENBERG, Mace L, SMALL, Eric J, RUBIN, Eric H, BASELGA, Jose, ROJO, Federico, WAUN KI HONG, SWAISLAND, Helen, AVERBUCH, Steven D
Published in Journal of clinical oncology (15.09.2002)
Published in Journal of clinical oncology (15.09.2002)
Get full text
Journal Article
A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors
Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., McCormack, P., Swaisland, H., Carmichael, J., Ranson, M.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article